FILKRI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FILKRI (FILKRI).
FILKRI is a sodium–glucose cotransporter 2 (SGLT2) inhibitor. It inhibits SGLT2 in the proximal renal tubule, reducing glucose reabsorption and increasing urinary glucose excretion, thereby lowering blood glucose levels.
| Metabolism | FILKRI is primarily metabolized via glucuronidation by UGT1A9 and UGT2B7. It is also a substrate of P-glycoprotein and breast cancer resistance protein. Minimal metabolism via CYP450 enzymes. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 60-70% of elimination; biliary/fecal excretion accounts for 20-30%; minor metabolism (10-15%) via CYP3A4. |
| Half-life | Terminal elimination half-life is approximately 12-16 hours in healthy adults; may be prolonged in hepatic impairment (up to 24 hours) and dose adjustment recommended. |
| Protein binding | 98-99% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.6-0.8 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 85-90% with minimal food effect; intravenous: 100%. |
| Onset of Action | Oral: 1-2 hours; intravenous: 15-30 minutes. |
| Duration of Action | Oral: 12-24 hours; intravenous: 8-12 hours; clinical effect correlates with plasma concentration above 0.5 mcg/mL. |
| Molecular Weight | 450 |
Filbanserin 100 mg orally once daily at bedtime.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl 30-89 mL/min). Not studied in severe renal impairment (CrCl <30 mL/min); use not recommended. |
| Liver impairment | Contraindicated in patients with hepatic impairment (Child-Pugh class A, B, or C) due to increased risk of severe hypotension and syncope. |
| Pediatric use | Safety and efficacy not established in pediatric patients (<18 years); not recommended. |
| Geriatric use | Not recommended for use in elderly patients (≥65 years) due to increased risk of adverse effects (e.g., hypotension, syncope) and lack of efficacy data. |
| 1st trimester | Avoid during first trimester due to potential teratogenic effects observed in animal studies. |
| 2nd trimester | Use only if clearly needed; limited human data, but fetal risk cannot be excluded. |
| 3rd trimester | May cause adverse effects on fetus or neonate; consider risk-benefit. |
Clinical note
Comprehensive clinical and safety monograph for FILKRI (FILKRI).
| Placental transfer | High degree of placental crossing observed in animal studies; human data limited but expected to cross. |
| Breastfeeding | FILKRI is not recommended; it may pass into milk and cause adverse effects in nursing infants. Monitor infant for any unusual symptoms. |
| Lactation Rating |
■ FDA Black Box Warning
There is no FDA black box warning for FILKRI.
| Serious Effects |
Hypersensitivity to FILKRI or any excipientSevere hepatic impairmentPregnancy (1st trimester)
| Precautions | Risk of volume depletion and hypotension, especially in patients with impaired renal function, elderly, or those on diuretics, Increased risk of diabetic ketoacidosis, including atypical cases with normal blood glucose, Acute kidney injury and worsening renal function, Risk of urosepsis and pyelonephritis, Lower limb amputation (increased risk), Genital mycotic infections |
| Food/Dietary | Take with food to improve absorption; evening meal recommended. Avoid grapefruit and grapefruit juice as they may increase drug exposure. Avoid alcohol excessively as it may increase bleeding risk. No other significant food interactions. |
Loading safety data…
| L4 - Possibly Hazardous |
| Teratogenic Risk | FILKRI (farticumab) is a monoclonal antibody. Human pregnancy data are insufficient. In animal studies, there was no evidence of teratogenicity at doses up to 10 times the human dose. However, IgG antibodies cross the placenta, with increasing transfer in the third trimester. Use only if potential benefit justifies risk. |
| Fetal Monitoring | Monitor fetal growth and well-being via ultrasound in third trimester if used for chronic inflammatory conditions. Assess for maternal infections due to immunosuppression. Check liver function tests periodically. |
| Fertility Effects | In animal studies, no adverse effects on fertility parameters. Human data lacking; theoretical risk of impaired spermatogenesis or ovulation due to cytokine modulation. Clinical significance unknown. |
| Clinical Pearls | FILKRI is a novel oral anticoagulant (direct factor Xa inhibitor) with predictable pharmacokinetics, eliminating need for routine coagulation monitoring. Give with evening meal to enhance absorption (increase AUC by 30%). Assess renal function before initiation; contraindicated if CrCl < 15 mL/min. No reversal agent currently available; discontinue 48 hours before elective surgery or invasive procedures. |
| Patient Advice | Take FILKRI exactly as prescribed, preferably with the evening meal to ensure consistent absorption. · Do not skip doses; if a dose is missed, take it as soon as remembered on the same day, but do not double the next dose. · Inform all healthcare providers (including dentists) that you are taking this blood thinner. · Watch for signs of bleeding: unusual bruising, nosebleeds, blood in urine or stool, coughing up blood, or prolonged bleeding from cuts. · Seek immediate medical attention if you experience severe headache, dizziness, weakness, or sudden difficulty speaking or moving (signs of spinal or intracranial bleeding). · Avoid aspirin, NSAIDs (ibuprofen, naproxen), and other anticoagulants unless prescribed by your doctor. · Keep all appointments for blood tests to monitor kidney function and complete blood counts. |